BTG Pharmaceuticals, a SERB company, to present data on ricin antidote development programme at the North American Congress of Clinical Toxicology
21 sept. 2023 06h42 HE
|
BTG Specialty Pharmaceuticals
West Conshohocken, PA, Sept. 21, 2023 (GLOBE NEWSWIRE) -- BTG Pharmaceuticals, a SERB company, announced today that SERB will present in vivo data for PR022, a polyclonal antibody in development as...
BTG Pharmaceuticals Statement on NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Recommendation for Use of Glucarpidase (Voraxaze®) and MTXPK.org
22 juin 2023 08h28 HE
|
BTG Specialty Pharmaceuticals
West Conshohocken, PA, June 22, 2023 (GLOBE NEWSWIRE) -- BTG Pharmaceuticals, a SERB company, highlights the recent updates to the National Comprehensive Cancer Network (NCCN) Guidelines for Acute...
New Publication Compares Total Vials of CroFab® and Anavip® Administered to Treat US Rattlesnake Envenomation
02 mai 2023 08h12 HE
|
BTG Specialty Pharmaceuticals
West Conshohocken, PA, May 02, 2023 (GLOBE NEWSWIRE) -- BTG Pharmaceuticals, a SERB company, today announced the publication of a new analysis of data from the American College of Medical...
New economic analysis of Voraxaze® (glucarpidase) in patients with delayed methotrexate
15 mars 2023 09h58 HE
|
BTG Specialty Pharmaceuticals
West Conshohocken, PA, March 15, 2023 (GLOBE NEWSWIRE) -- BTG Pharmaceuticals, a SERB company, today announces the publication of an economic simulation assessing the value of Voraxaze®...
SERB Pharmaceuticals licenses Soligenix antigen to develop ricin antidote
14 juil. 2022 07h01 HE
|
BTG Specialty Pharmaceuticals
Philadelphia, July 14, 2022 (GLOBE NEWSWIRE) -- SERB Pharmaceuticals has signed a worldwide exclusive license to use an antigen from Soligenix [NSDQ: SNGX] to develop a novel therapeutic treatment...
Four Independent Studies of Voraxaze® Published at European Hematology Conference 2022
09 juin 2022 04h49 HE
|
BTG Specialty Pharmaceuticals
Vienna, June 09, 2022 (GLOBE NEWSWIRE) -- The European Hematology Association (EHA) Conference published four independent studies of Voraxaze® (glucarpidase) by various investigators for inclusion...
Thomas Kolaras Joins SERB and BTG Specialty Pharmaceuticals as US Chief Commercial Officer
11 avr. 2022 07h10 HE
|
BTG Specialty Pharmaceuticals
Philadelphia, April 11, 2022 (GLOBE NEWSWIRE) -- SERB and BTG Specialty Pharmaceuticals are pleased to announce that Thomas Kolaras has been named the group’s new Chief Commercial Officer for its US...
SERB acquires the rights to Xermelo® outside US and Japan for Carcinoid Syndrome Diarrhoea
04 avr. 2022 02h08 HE
|
BTG Specialty Pharmaceuticals
Paris, April 04, 2022 (GLOBE NEWSWIRE) -- SERB is pleased to announce it has acquired the rights from Ipsen to commercialize Xermelo® (telotristat ethyl) in Europe and other countries outside the US...
SERB receives EU approval for Voraxaze® (glucarpidase) as Rescue Therapy for High Dose Methotrexate Toxicity
14 janv. 2022 11h10 HE
|
BTG Specialty Pharmaceuticals
London, Jan. 14, 2022 (GLOBE NEWSWIRE) -- SERB and BTG Specialty Pharmaceuticals today announced that the European Commission has granted marketing authorisation for Voraxaze® (glucarpidase) to...
Se presenta la primera evidencia de toxicidad relacionada con el metotrexato en dosis elevadas en España durante la Virtual ISPOR Europe 2021
02 déc. 2021 03h45 HE
|
BTG Specialty Pharmaceuticals
COPENHAGUE, Dinamarca, Dec. 02, 2021 (GLOBE NEWSWIRE) -- La primera evidencia de la toxicidad relacionada con el metotrexato en dosis elevadas (HDMTX) en España se expuso hoy en la Virtual ISPOR...